SCHEMBL10045562

SCHEMBL10045562

Cc1cc(COc2ccccn2)c2cccc(O)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.45
BDKRB2 P30411 1/20 0.43
NPC1 O15118 6/20 0.42
HTT P42858 4/20 0.42
RAB9A P51151 4/20 0.42
ALOX12 P18054 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MAPT P10636 4/20 0.40
LMNA P02545 4/20 0.40
TSHR P16473 3/20 0.40
TP53 P04637 2/20 0.40
L3MBTL1 Q9Y468 7/20 0.39
BRD4 O60885 1/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6639396 0.80 KDM4E (0.52) KDM4ENPC1HTTRAB9AALOX12
SCHEMBL6640320 0.76 KMT2A (0.57) KDM4ENPC1HTTRAB9AALOX12
SCHEMBL2877622 0.75 KDM4E (0.47) KDM4EALOX12MAPTLMNATSHR
SCHEMBL30587191 0.75 KDM4E (0.47) KDM4EALOX12MAPTLMNATSHR
SCHEMBL6965159 0.75 SYK (0.47) KDM4EBDKRB2MAPTSMN1; SMN2
SCHEMBL8024297 0.74 KDM4E (0.46) KDM4EALOX12MAPTLMNATSHR
SCHEMBL8072010 0.74 KDM4E (0.46) KDM4EALOX12MAPTLMNATSHR
SCHEMBL27527696 0.74 KDM4E (0.46) KDM4EALOX12MAPTLMNATSHR
SCHEMBL28795511 0.73 IDO1 (0.50) KDM4ENPC1MAPTTSHRL3MBTL1
SCHEMBL660152 0.72 KDM4E (0.44) KDM4EHTTRAB9AALOX12NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252793-B2 Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma ALCON RESEARCH, LTD. (US) 2012-08-28 US disclosed
US-8252793-B2 Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma ALCON RESEARCH, LTD. (US) 2012-08-28 US disclosed
US-20120046285-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
US-20120046285-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046285-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA BDKRB2, BDKRB1, PTGIR KDM4E 3092/4885BDKRB2 1/4885NPC1 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.